Mylan Announces U.S. PTO Intends to Reissue Two Perforomist Patents to Dey Pharma

BASKING RIDGE, N.J., Aug. 2, 2011 /PRNewswire/ -- Dey Pharma
L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today announced
that the U.S. Patent and Trademark Office intends to reissue both
of the patents related to Perforomist® (formoterol fumarate)
Inhalation Solution 20 mcg/2mL vial that had been placed into
reexamination by Sepracor, now known as Sunovion Pharmaceuticals.
Including the two expected reissued patents, Dey believes that
seven U.S. patents are infringed by Sunovion's Brovana®
product. In addition, Dey believes that Teva's formotorol fumarate
product pending before the FDA also infringes several of Dey's U.S.
patents. The terms of the patents protecting Perforomist®
extend into 2021.

Mylan Chairman and CEO Robert J. Coury commented: "We are very
pleased with today's decision by the U.S. PTO in relation to
intellectual property protecting Perforomist®, as well as our
combination product for the treatment of Chronic Obstructive
Pulmonary Disease (COPD), currently in development. We look forward
to continuing to assert our very strong IP related to these
products in the pending patent litigations against Sunovion and
Teva. Today's developments further strengthen the potential of the
Dey franchise and its portfolio of products."

About Dey Pharma

Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a
specialty pharmaceutical company focused on the development,
manufacturing and marketing of prescription drug products for the
treatment of respiratory diseases, severe allergic reactions and
psychiatric disorders. The company puts patients first and
facilitates efficient, cost-effective partnerships with customers.
For more information, please visit www.dey.com.

About Mylan

Mylan Inc. ranks among the leading generic and specialty
pharmaceutical companies in the world and provides products to
customers in more than 150 countries and territories. The company
maintains one of the industry's broadest and highest quality
product portfolios supported by a robust product pipeline; operates
one of the world's largest active pharmaceutical ingredient
manufacturers; and runs a specialty business focused on
respiratory, allergy and psychiatric therapies. For more
information about Mylan, please visit www.mylan.com.

Forward Looking Statements

This press release includes statements that constitute
"forward-looking statements", including with regard to pending
litigation, products in development and expectations for Dey's
future. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Because such statements inherently involve risks and uncertainties,
actual future results may differ materially from those expressed or
implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to: uncertainties inherent in legal proceedings; other
legal or regulatory challenges; the impacts of competition; changes
in economic and financial conditions of the company's business; and
the other risks detailed in the Company's periodic filings with the
Securities and Exchange Commission. The company undertakes no
obligation to update these statements for revisions or changes
after the date of this release.